Scenic Biotech announced that it has entered into a research collaboration with Bristol Myers Squibb to accelerate the development of Bristol Myers Squibb's drug targets by identifying target biology for indication selection and expansion. Under the terms of the agreement, Scenic Biotech will be entitled to an upfront payment and potential additional payments contingent upon achievement of a range of research, development and commercial milestones.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.01 USD | -0.23% | -2.07% | -14.23% |
May. 16 | Everlasting momentum | |
May. 16 | Bristol Myers Gets FDA OK of Breyanzi in Follicular Lymphoma | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.23% | 89.25B | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Scenic Biotech Enters into Research Collaboration with Bristol Myers Squibb